Treating patients with cancer is often challenging yet rewarding work. But caring for patients in an urban setting, where some patients don’t speak English and other patients aren’t fully insured and possibly facing significant financial challenges.
Treating patients with cancer is often challenging yet rewarding work. But caring for patients in an urban setting, where some patients don’t speak English and other patients aren’t fully insured and possibly facing significant financial challenges, can make it even more difficult to provide high quality patient care.
Take, for example, Montefiore Medical Center in Bronx, New York. Eighty percent of its patients are considered minorities, says Aditi Shastri, MD, an oncologist who specializes in the treatment of blood-related cancers at the medical center.
Specifically, many of the patients she treats are African American, Afro-Caribbean, and Hispanic. In addition, the median annual household income among Bronx residents is under $38,000 and the area has a 28.7% poverty rate.
Creating and sustaining a workforce that looks and talks like the patients treated at your hospital can help engage them in their own care, says Shastri.
Here are three other ways Shastri and her colleagues at Montefiore Medical Center are serving their patients’ specific needs:
Providing consent forms in patients’ native languages. To increase participation from minority populations in clinical trials, Montefiore Medical Center provides patient consent forms in the languages spoken by its patients. It’s standard practice to provide forms in Spanish, which is spoken by many of the health system’s patients. And recently, Montefiore Medical Center worked directly with the company sponsoring a clinical trial to translate these forms into Mandarin, which was the only language spoken by a patient who was interested in participating in the clinical trial.
Connecting patients with socioeconomic support. Shastri and her colleagues have to be sensitive to their patients’ needs and provide support to improve their clinical outcomes, she says. That means she needs to partner with social workers on her team to assist with patients experiencing housing instability and “financial toxicity” due to their cancer treatments.
For example, one of her patients experiences myelodysplastic syndromes, which the American Cancer Society describes as a type of cancer that’s caused when blood-forming cells in bone marrow become abnormal. When Shastri was talking to this patient recently, she discovered that he was spending at least $1,000 a month on medication for his gastrointestinal condition. Upon learning this, she worked with a social worker on her team and the patient’s gastroenterologist to convince the pharmaceutical company to offer more compassionate pricing for this medication.
In addition, some of her younger patients about to start chemotherapy treatments discover that fertility procedures such as sperm banking and ovarian harvesting aren’t covered by their insurance. For patients who want to have children in the future, this is a very important issue, says Shastri, and one where she also partners with her team’s social workers to secure financial support for these fertility preservation procedures.
Working with legal resources to secure insurance coverage. Another challenge faced by some of Shastri’s patients is that they were born outside the United States and are living in the country on an undocumented basis. Thus, they need help securing health insurance for life-saving procedures such as bone marrow transplants. That means she needs to liaise directly with lawyers to get insurance coverage for these patients.
Cancer’s Reign Over the Drug Development Pipeline Continues| AMCP Nexus 2024
October 18th 2024The FDA has already made more than a dozen cancer drug approval decisions this year and more expected in the next several months and in early 2025, according to Kaelyn Boss, who gave an oncology drug pipeline talk at the 2024 AMCP Nexus meeting this week.
Read More
Using the 'Pathway' Approach to Shorten the Time Between Cancer Diagnosis and Treatment
November 16th 2022In this episode of Tuning In to the C-Suite, Briana Contreras, editor with Managed Healthcare Executive spoke with Dr. Yuri Fesko, oncologist and vice president of Medical Affairs at Quest Diagnostics. In the conversation, Dr. Fesko addressed the ongoing issue of long gaps of times between receiving a diagnosis for a type of cancer and finally getting the treatment for it. Dr. Fesko shared the benefits a number of sectors receive when treating patients sooner and the steps to get there.
Listen
Verastem Begins Submission for Ovarian Cancer Combination
May 24th 2024Verastem is studying the combination of avutometinib and defactinib to treat low-grade serous ovarian cancer in patients with KRAS-mutations. The company plans to complete the new drug application in the second half of this year.
Read More